Page 2 - Rupesh Kotecha News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rupesh kotecha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rupesh Kotecha Today - Breaking & Trending Today

ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting

/PRNewswire/ ViewRay, Inc. (Nasdaq: VRAY) announced today that the company s MRIdian MRI-guided radiation therapy system will be featured at the Annual. ....

United States , Genesiscare Oxford , Thierry Gevaert , Moran Debby , Rupesh Kotecha , Luca Boldrini , Philip Camilleri , Stefanie Corradini , Assuta Medical Center , Ludwig Maximilian University , Messe Congress Center , Miami Cancer Institute , Meeting Of The European Society For Radiotherapy , Moffitt Cancer Center , Heidelberg University Hospital , Prnewswire Viewray Inc , Viewray Inc , Annual Meeting , European Society , Radiation Therapy , Lorenzo Placidi , James Good , Moffitt Cancer , Ludwig Maximilian , Miami Cancer , Heidelberg University ,

Educated Patient® Breast Cancer Summit at MBCC Treating Brain Metastases Presentation: March 4, 2023

Watch Dr. Rupesh Kotecha, from Miami Cancer Institute, Baptist Health South Florida, discuss the treatment of brain metastases during the CURE Educated Patient® Breast Cancer Summit at MBCC. ....

United States , Rupesh Kotecha , Baptist Health South Florida , Miami Cancer Institute , Educated Patient , Breast Cancer Conference , Miami Breast Cancer , Trials Drive Progress , Metastatic Breast ,

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

/PRNewswire/ Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other. ....

Florida Keys , United States , Rupesh Kotecha , Stepheng Marcus , Bianca Hernandez , Casey Mcdonald , Jon Nugent , Prnewswire Cantex Pharmaceuticals Inc , Cantex Pharmaceuticals , Drug Administration , Baptist Health Miami Cancer Institute , Baptist Health Cancer Care , Tv Therapeutics Inc , Miami Cancer Institute , Cantex Pharmaceuticals Inc , Department Of Radiation Oncology , South Florida , Radiation Oncology , Central Nervous System Metastasis , Miami Cancer , Chief Executive Officer , Drug Designation , Cancer Institute , Latin America , Memorial Sloan Kettering Cancer , Baptist Health Cancer ,

Preop Stereotactic Radiotherapy Tied to Improved Brain Metastases Outcomes

In cancer patients with brain metastases, preoperative stereotactic radiotherapy is associated with improved outcomes compared to no SRT, a small trial shows. ....

United States , San Francisco , John Suh , Rupesh Kotecha , Steve Braunstein , Reuters Health , Baptist Health South Florida , Miami Cancer Institute , Program University Of California , Radiation Oncology , Cleveland Clinic , Co Director University , Scientific Reports , Lung Cancer , Ung Carcinoma , Ancer Of The Lung , Radiation Therapy , Radiation Oncology , Brain Metastasis , Metastatic Brain Tumor , Etastatic Disease To The Brain , Rain Metastases Metastatic Brain Tumour , Alignant Neoplasia , Alignant Neoplasm , Breast Cancer , Alignant Breast Neoplasm ,

Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer

(0)
Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck Co., Inc., Kenilworth, NJ, USA). Novocure also announced the members of its scientific steering committee who will provide expert opinions and recommendations regarding enrollment strategies, country distribution, study timelines and other scientific topics. The KEYNOTE-B36 trial will evaluate Tumor Treating Fields (TTFields) together with pembrolizumab for first-line treatment of locally advanced or metastatic intrathoracic, PD-L1 positive non-small cell lung cancer (NSCLC).
KEYNOTE-B36 steering committee members include:
Corey Langer, M.D., director of thoracic oncology and professor of medicine at the Hospital of the University of Pennsylvania ....

United States , New York , New Hampshire , University Of Pennsylvania , Corey Langer , Rupesh Kotecha , Adam Daney , Vinicius Ernani , Annes Tsao , Asaf Danziger , University Of Texas Md Anderson Cancer Center , Md Anderson Conflict Of Interest Committee , Drug Administration , Merck Co Inc , Exchange Commission , Miami Cancer Institute , Hospital Of The University Pennsylvania , Tumor Treating Fields , Cancer Center , Senior Associate Consultant , Mayo Clinic , Chief Executive , Treating Fields , Tumor Treating , Annual Report , Private Securities Litigation Reform Act ,